Global RNAi Technology Market Projected to Grow at 14% CAGR Through 2034, Driven by Drug Approvals and Delivery Innovations

The global market for RNA interference (RNAi) technology is on track for significant expansion, with a projected compound annual growth rate of roughly 14% through 2034, according to a new report from DelveInsight.

Market Drivers

The growth is largely attributed to the increasing number of approved and commercialized RNAi-based therapeutics targeting rare genetic disorders, metabolic conditions, cardiovascular diseases, and liver diseases. RNAi technology enables highly specific gene silencing, allowing treatments to address the root causes of disease rather than merely alleviating symptoms. This precision has driven its adoption in areas such as oncology, rare genetic diseases, and chronic conditions where few effective options exist.

Regulatory agencies have also supported RNA-based therapies through accelerated approval pathways, orphan drug designations, and fast-track programs, encouraging faster clinical development and market entry. At the same time, a rising global burden of cancers, cardiovascular ailments, and rare inherited disorders is fueling demand for innovative treatment approaches.

Technological Advances and Investment

Key innovations in delivery platforms—particularly lipid nanoparticles (LNPs) and GalNAc conjugates—have dramatically improved the stability, specificity, and safety of RNAi therapeutics. These advances have overcome long-standing delivery challenges and broadened the range of diseases that can be targeted.

The report highlights accelerating investment from pharmaceutical and biotechnology companies, alongside growing collaborations between industry, academia, and research organizations. Strong venture capital funding, government grants, and private investments are enabling companies to expand clinical programs, manufacturing capacity, and global reach.

Expanding Applications and Strategic Partnerships

Initially concentrated on rare genetic diseases, RNAi technology is now being explored across a wide spectrum of conditions, including oncology, infectious diseases, neurological disorders, ophthalmology, and metabolic syndromes. This expanding application landscape is creating significant long-term opportunities.

Strategic collaborations and licensing agreements between biotechnology firms, pharmaceutical companies, and technology providers are enhancing access to RNAi platforms and delivery technologies, reducing development risks and accelerating pipeline progress.

Regional Dominance

North America led the global RNAi technology market in 2025, capturing approximately 45% of total revenue. The region's dominance is supported by a strong presence of key companies, robust research infrastructure, and favorable regulatory conditions.

Key players in the market, as noted in the report, include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Novo Nordisk (through Dicerna), Silence Therapeutics, Novartis, Ionis Pharmaceuticals, Thermo Fisher Scientific, Merck KGaA, Sirnaomics, Sanofi, and others.